Polpharma and Fresenius Kabi License Vedolizumab Biosimilar
August 5, 2025
Polpharma Biologics S.A. has announced a global licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab. The agreement excludes
